MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    The effect of improved nutritional status on psychiatric features and quality of life in Parkinson’s disease patients

    N. Ongun, C. Erdogan, E. Degirmenci, L.S. Bir (Denizli, Turkey)

    Objective: To determine the effect of nutritional status in 6 weeks time on depression, anxiety and quality of life in Parkinson's disease (PD) patients. Background:…
  • 2016 International Congress

    ECG-based cardiopulmonary coupling for sleep stability assessment in patients with amyotrophic lateral sclerosis

    S. Mariani, P. Congiu, G. Milioli, G. Gioi, G. Borghero, F. Marrosu, R.J. Thomas, A.L. Goldberger, M. Puligheddu (Boston, MA, USA)

    Objective: The goal of this preliminary study is to introduce the technique of CardioPulmonary Coupling (CPC) to visualize and quantify the sleep spectrograms of Amyotrophic…
  • 2016 International Congress

    Physiotherapy can reduce the decline in functioning according to ICF framework in patients in early stage of Parkinson’s disease evolution

    E.T.N. Guelfi, E. Okamoto, F.B. Tarallo, J.C. Elmauer, R.R. Fermino, V.F. Giangiardi, P. Yuki, E.P. Piemonte (São Paulo, Brazil)

    Objective: To investigate the effects of physiotherapy treatment on functioning according to International Classification of Functioning, Disability and Health (ICF) framework in patients in early…
  • 2016 International Congress

    Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia

    G. Gangarossa, M. Guzman, V. Prado, M. Prado, S. Daumas, S. El Mestikawy, E. Valjent (Paris, France)

    Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…
  • 2016 International Congress

    An ongoing phase 2, multi-centre, open-label, study of WTX101 in Wilson disease patients – Early observations

    A. Czlonkowska, K.H. Weiss, A. Ala, F. Askari, D. Nicholl, M.L. Schilsky (Warsaw, Poland)

    Objective: The aim of this ongoing study is to evaluate the efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients. Background: WTX101 (bis-choline…
  • 2016 International Congress

    Supplement use in PD is associated with delayed initiation of dopaminergic therapy

    L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

    Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…
  • 2016 International Congress

    Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

    G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

    Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…
  • 2016 International Congress

    Effectiveness of a multidisciplinary PD clinic in improving quality of life

    H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

    Objective: To evaluate the effectiveness of a multidisciplinary PD clinic in a tertiary hospital in Hong Kong. Background: Parkinson's disease (PD) has been recognized as…
  • 2016 International Congress

    Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

    S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

    Objective: To determine which factors predict medication reduction for Parkinson's disease (PD) patients after deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN). Background:…
  • 2016 International Congress

    Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Nilotinib, a tyrosine kinase inhibitor (TKI) was examined with the aim of showing its effect on safety comparing a lower dose of 150mg (N=6)…
  • « Previous Page
  • 1
  • …
  • 126
  • 127
  • 128
  • 129
  • 130
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #26133 (not found)
  • #23951 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley